JAK kinases in leukemias/lymphomas and multiple myeloma / Renate Burger, Martin Gramatzki -- Glivec (Gleevec, Imatinib, STI571) : a targeted therapy for CML / Elisabeth Buchdunger, Renaud Capedeville -- Platelet-derived growth factor : normal function, role in disease, and applications of PDGF antagonists / Tobias Sjoblom [and others] -- Structural biology of protein tyrosine kinases / Sandra W. Cowan-Jacob [and others] -- Testing of signal transduction inhibitors in animal models of cancer / Terence O'Reilly, Robert Cozens -- Phosphoproteomics in drug discovery and development / Michel F. Moran.
Protein tyrosine kinases as targets for cancer and other indications / Mark Pearson, Carlos Garcia-Echeverria, Doriano Fabbro -- Inhibitors of signaling interfaces : targeting Src homology 2 domains in drug discovery / Carlos Garcia-Echeverria -- PI 3-kinase inhibition : a target for therapeutic intervention / Peter M. Finan, Stephen G. Ward -- Src as a target for pharmaceutical intervention : potential and limitations / Mira Susa [and others] -- Activated FLT3 receptor tyrosine kinase as a therapeutic target in leukemia / Blanca Scheijen, James D. Griffin.
0
0
In this title, leading researchers, from the Novartis group that pioneered Gleevec/Gliveca and around the world, comprehensively survey the state of the art in the drug discovery processes (bio- and chemoinformatics, structural biology, profiling, generation of resistance, etc.) aimed at generating PTK inhibitors for the treatment of various diseases, including cancer. Highlights include a discussion of the rationale and the progress made towards generating 'selective' low molecular-weight kinase inhibitors; an analysis of the normal function, role in disease, and application of platelet-deriv.